|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hernandez BY, Zhu X, Goodman MT, Gatewood
R, Mendiola P, Quinata K and Paulino YC: Betel nut chewing, oral
premalignant lesions, and the oral microbiome. PLoS One.
12:e01721962017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Usman S, Jamal A, The MT and Waseem A:
Major molecular signaling pathways in oral cancer associated with
therapeutic resistance. Front Oral Health. 1:6031602021. View Article : Google Scholar
|
|
4
|
Hanna GJ, Patel N, Tedla SG, Baugnon KL,
Aiken A and Agrawal N: Personalizing surveillance in head and neck
cancer. Am Soc Clin Oncol Educ Book. 43:e3897182023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gormley M, Creaney G, Schache A,
Ingarfield K and Conway DI: Reviewing the epidemiology of head and
neck cancer: Definitions, trends and risk factors. Br Dent J.
233:780–786. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu H, Lv M and Tian X: A review on
hemisynthesis, biosynthesis, biological activities, mode of action,
and structure-activity relationship of podophyllotoxins: 2003-2007.
Curr Med Chem. 16:327–349. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
King ML and Sullivan MM: The similarity of
the effect of podophyllin and colchicine and their use in the
treatment of condylomata acuminata. Science. 104:244–245. 1946.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Desbène S and Giorgi-Renault S: Drugs that
inhibit tubulin polymerization: The particular case of
podophyllotoxin and analogues. Curr Med Chem Anticancer Agents.
2:71–90. 2002. View Article : Google Scholar
|
|
9
|
Chen SW, Wang YH, Jin Y, Tian X, Zheng YT,
Luo DQ and Tu YQ: Synthesis and anti-HIV-1 activities of novel
podophyllotoxin derivatives. Bioorg Med Chem Lett. 17:2091–2095.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu H and Xiao X: Natural products-based
insecticidal agents 4. Semisynthesis and insecticidal activity of
novel esters of 2-chloropodophyllotoxin against Mythimna separata
Walker in vivo. Bioorg Med Chem Lett. 19:5415–5418. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao W, Cong Y, Li HM, Li S, Shen Y, Qi Q,
Zhang Y, Li YZ and Tang YJ: Challenges and potential for improving
the druggability of podophyllotoxin-derived drugs in cancer
chemotherapy. Nat Prod Rep. 38:470–488. 2021. View Article : Google Scholar
|
|
12
|
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N,
Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH,
et al: Durvalumab plus platinum-etoposide versus platinum-etoposide
in first-line treatment of extensive-stage small-cell lung cancer
(CASPIAN): A randomised, controlled, open-label, phase 3 trial.
Lancet. 394:1929–1939. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Conlon KC, Sportes C, Brechbiel MW, Fowler
DH, Gress R, Miljkovic MD, Chen CC, Whatley MA, Bryant BR, Corcoran
EM, et al: 90Y-daclizumab (anti-CD25), high-dose
carmustine, etoposide, cytarabine, and melphalan chemotherapy and
autologous hematopoietic stem cell transplant yielded sustained
complete remissions in 4 patients with recurrent Hodgkin's
lymphoma. Cancer Biother Radiopharm. 35:249–261. 2020.PubMed/NCBI
|
|
14
|
Tsukamoto Y, Kiyasu J, Choi I, Kozuru M,
Uike N, Utsunomiya H, Hirata A, Fujioka E, Ohno H, Nakashima E, et
al: Efficacy and safety of the modified EPOCH regimen (etoposide,
vincristine, doxorubicin, carboplatin, and prednisolone) for adult
T-cell leukemia/lymphoma: A multicenter retrospective study. Clin
Lymphoma Myeloma Leuk. 20:e445–e453. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L,
Shi A, Jiang W, Xu Y, Zhou Z, et al: Etoposide and cisplatin versus
paclitaxel and carboplatin with concurrent thoracic radiotherapy in
unresectable stage III non-small cell lung cancer: A multicenter
randomized phase III trial. Ann Oncol. 28:777–783. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Manapov F and Eze C: Survival advantage
for etoposide/cisplatin over paclitaxel/carboplatin concurrent
chemoradiation in patients with inoperable stage III NSCLC: A
subgroup analysis for ECOG 2 patients would be of great interest.
Ann Oncol. 28:2319–2320. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bugg BY, Danks MK, Beck WT and Suttle DP:
Expression of a mutant DNA topoisomerase II in CCRF-CEM human
leukemic cells selected for resistance to teniposide. Proc Natl
Acad Sci USA. 88:7654–7658. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kamal A, Nayak VL, Bagul C, Vishnuvardhan
MV and Mallareddy A: Investigation of the mechanism and apoptotic
pathway induced by 4β cinnamido linked podophyllotoxins against
human lung cancer cells A549. Apoptosis. 20:1518–1529. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Sun H, Xiao Z, Zhang D, Bao X and
Wei N: XWL-1-48 exerts antitumor activity via targeting
topoisomerase II and enhancing degradation of Mdm2 in human
hepatocellular carcinoma. Sci Rep. 7:99892017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bai G and Zhao D, Ran X, Zhang L and Zhao
D: Novel hybrids of podophyllotoxin and coumarin inhibit the growth
and migration of human oral squamous carcinoma cells. Front Chem.
8:6260752021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Choi SJ, Swarup N, Shin JA, Hong SD and
Cho SD: Myeloid cell leukemia-1 expression in cancers of the oral
cavity: A scoping review. Cancer Cell Int. 22:1822022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shin JA, Jung JY, Ryu MH, Safe S and Cho
SD: Mithramycin A inhibits myeloid cell leukemia-1 to induce
apoptosis in oral squamous cell carcinomas and tumor xenograft
through activation of Bax and oligomerization. Mol Pharmacol.
83:33–41. 2013. View Article : Google Scholar
|
|
23
|
Yang IH, Jung W, Kim LH, Shin JA, Cho NP,
Hong SD, Hong KO and Cho SD: Nitidine chloride represses Mcl-1
protein via lysosomal degradation in oral squamous cell carcinoma.
J Oral Pathol Med. 47:823–829. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jung M, Han DJ, Ahn CH, Hong KO, Choi YS,
Kim JS, Yoon HJ, Hong SD, Shin JA and Cho SD: In vitro induction of
mitotic catastrophe as a therapeutic approach for oral cancer using
the ethanolic extract of Juniperus squamata. Oncol Rep. 45:1032021.
View Article : Google Scholar
|
|
25
|
Wei AH, Roberts AW, Spencer A, Rosenberg
AS, Siegel D, Walter RB, Caenepeel S, Hughes P, McIver Z, Mezzi K,
et al: Targeting MCL-1 in hematologic malignancies: Rationale and
progress. Blood Rev. 44:1006722020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Campbell KJ, Dhayade S, Ferrari N, Sims
AH, Johnson E, Mason SM, Dickson A, Ryan KM, Kalna G, Edwards J, et
al: MCL-1 is a prognostic indicator and drug target in breast
cancer. Cell Death Dis. 9:192018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wein L and Loi S: Mechanisms of resistance
of chemotherapy in early-stage triple negative breast cancer
(TNBC). Breast. 34(Suppl 1): S27–S30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nakano T, Go T, Nakashima N, Liu D and
Yokomise H: Overexpression of antiapoptotic MCL-1 predicts worse
overall survival of patients with non-small cell lung cancer.
Anticancer Res. 40:1007–1014. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee WS, Park YL, Kim N, Oh HH, Son DJ, Kim
MY, Oak CY, Chung CY, Park HC, Kim JS, et al: Myeloid cell
leukemia-1 is associated with tumor progression by inhibiting
apoptosis and enhancing angiogenesis in colorectal cancer. Am J
Cancer Res. 5:101–113. 2014.
|
|
30
|
Perciavalle RM and Opferman JT: Delving
deeper: MCL-1's contributions to normal and cancer biology. Trends
Cell Biol. 23:22–29. 2013. View Article : Google Scholar
|
|
31
|
Levine B, Sinha S and Kroemer G: Bcl-2
family members: Dual regulators of apoptosis and autophagy.
Autophagy. 4:600–606. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Willis SN, Chen L, Dewson G, Wei A, Naik
E, Fletcher JI, Adams JM and Huang DC: Proapoptotic Bak is
sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by
BH3-only proteins. Genes Dev. 19:1294–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
34
|
Wang C and Youle RJ: The role of
mitochondria in apoptosis*. Annu Rev Genet. 43:95–118. 2009.
View Article : Google Scholar
|
|
35
|
Wong RS: Apoptosis in cancer: From
pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hsu S, Singh B and Schuster G: Induction
of apoptosis in oral cancer cells: Agents and mechanisms for
potential therapy and prevention. Oral Oncol. 40:461–473. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang IH, Hong SH, Jung M, Ahn CH, Yoon HJ,
Hong SD, Cho SD and Shin JA: Cryptotanshinone chemosensitivity
potentiation by TW-37 in human oral cancer cell lines by targeting
STAT3-Mcl-1 signaling. Cancer Cell Int. 20:4052020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Choi SJ, Ahn CH, Yang IH, Jin B, Lee WW,
Kim JH, Ahn MH, Swarup N, Hong KO, Shin JA, et al: Pseudolaric acid
B induces growth inhibition and caspase-dependent apoptosis on head
and neck cancer cell lines through death receptor 5. Molecules.
24:37152019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Won DH, Chung SH, Shin JA, Hong KO, Yang
IH, Yun JW and Cho SD: Induction of sestrin 2 is associated with
fisetinmediated apoptosis in human head and neck cancer cell lines.
J Clin Biochem Nutr. 64:97–105. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kapałczyńska M, Kolenda T, Przybyła W,
Zajączkowska M, Teresiak A, Filas V, Ibbs M, Bliźniak R, Łuczewski
Ł and Lamperska K: 2D and 3D cell cultures-a comparison of
different types of cancer cell cultures. Arch Med Sci. 14:910–919.
2018.
|
|
41
|
Pang YQ, Lin H, Ou C, Cao Y, An B, Yan J
and Li X: Design, synthesis, and biological evaluation of novel
benzodiazepine derivatives as anticancer agents through inhibition
of tubulin polymerization in vitro and in vivo. Eur J Med Chem.
182:1116702019. View Article : Google Scholar
|
|
42
|
Mukhtar E, Adhami VM and Mukhtar H:
Targeting microtubules by natural agents for cancer therapy. Mol
Cancer Ther. 13:275–284. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang X, Rakesh KP, Shantharam CS,
Manukumar HM, Asiri AM, Marwani HM and Qin HL: Podophyllotoxin
derivatives as an excellent anticancer aspirant for future
chemotherapy: A key current imminent needs. Bioorg Med Chem.
26:340–355. 2018. View Article : Google Scholar
|
|
44
|
Xiao J, Gao M, Sun Z, Diao Q, Wang P and
Gao F: Recent advances of podophyllotoxin/epipodophyllotoxin
hybrids in anticancer activity, mode of action, and
structure-activity relationship: An update (2010-2020). Eur J Med
Chem. 208:1128302020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen JY, Tang YA, Li WS, Chiou YC, Shieh
JM and Wang YC: A synthetic podophyllotoxin derivative exerts
anti-cancer effects by inducing mitotic arrest and pro-apoptotic ER
stress in lung cancer preclinical models. PLoS One. 8:e620822013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ribeiro IP, Marques F, Barroso L,
Rodrigues J, Caramelo F, Melo JB and Carreira IM: Genomic profile
of oral squamous cell carcinomas with an adjacent leukoplakia or
with an erythroleukoplakia that evolved after the treatment of
primary tumor: A report of two cases. Mol Med Rep. 16:6780–6786.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shin JA, Seo JM, Oh S, Cho SD and Lee KE:
Myeloid cell leukemia-1 is a molecular indicator for malignant
transformation of oral lichen planus. Oncol Lett. 11:1603–1607.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nagata M, Wada K, Nakajima A, Nakajima N,
Kusayama M, Masuda T, Iida S, Okura M, Kogo M and Kamisaki Y: Role
of myeloid cell leukemia-1 in cell growth of squamous cell
carcinoma. J Pharmacol Sci. 110:344–353. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Shin JA, Kim JS, Kwon KH, Nam JS, Jung JY,
Cho NP and Cho SD: Apoptotic effect of hot water extract of
Sanguisorba officinalis L. in human oral cancer cells. Oncol Lett.
4:489–494. 2012. View Article : Google Scholar
|
|
50
|
Shin JA, Kim JJ, Choi ES, Shim JH, Ryu MH,
Kwon KH, Park HM, Seo JY, Lee SY, Lim DW, et al: In vitro apoptotic
effects of methanol extracts of Dianthus chinensis and Acalypha
australis L. targeting specificity protein 1 in human oral cancer
cells. Head Neck. 35:992–998. 2013. View Article : Google Scholar
|
|
51
|
Choi SJ, Ahn CH, Hong KO, Kim JH, Hong SD,
Shin JA and Cho SD: Molecular mechanism underlying the apoptotic
modulation by ethanol extract of Pseudolarix kaempferi in
mucoepidermoid carcinoma of the salivary glands. Cancer Cell Int.
21:4272021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wertz IE, Kusam S, Lam C, Okamoto T,
Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al:
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1
and FBW7. Nature. 471:110–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang W, Wang YQ, Meng T, Yi JM, Huan XJ,
Ma LP, Tong LJ, Chen Y, Ding J, Shen JK and Miao ZH: MCL-1
degradation mediated by JNK activation via MEKK1/TAK1-MKK4
contributes to anticancer activity of new tubulin inhibitor MT189.
Mol Cancer Ther. 13:1480–1491. 2014. View Article : Google Scholar : PubMed/NCBI
|
